New products, safer choices?
To help people understand the relative risks of different types of tobacco and nicotine products, they can be placed on a risk continuum model based on exposure to toxicants.
Cigarettes are by far the most harmful way to consume tobacco. Inhaling toxicants contained within the smoke causes the overwhelming majority of smoking-related disease.
These products contain tobacco that, instead of being burned, is heated to vaporise the nicotine into an inhalable aerosol. This provides the consumer with the taste and flavour of smoking but with far lower levels of toxicants.
Snus is a type of low-toxicant oral tobacco that we currently sell in Sweden and Norway. It is proven by independent health studies to be substantially less risky than smoking.
These contain an 'e-liquid', made up of nicotine and other ingredients, which is heated to deliver nicotine to the user in the form of vapour. They don't contain tobacco and there is no combustion, so there are significantly lower levels of toxicants.
These are nicotine products which are authorised as a medicine by the country's medicine regulator to help people reduce, replace or stop smoking. They are subject to strict regulations.
We are committed to researching, developing and commercialising less risky alternatives to regular cigarettes. For society, less risky alternatives have the potential to reduce smoking-related disease, while also being an area of commercial growth for our business.
We have invested significant time, funds and resources into developing high-quality Next Generation Products. We have made considerable progress in building our range and expanding into new markets.
In 2013, we were the first international tobacco company to launch a Vapour Product (e-cigarette) – Vype – in the UK. Since then, we have used our experience and insights to develop the range with new devices, such as the Vype ePen, eTank and eBox. We have also rolled Vype out to other markets, including Italy, France, Poland, Germany and Colombia.
In December 2016 we opened our first Vype-branded store – in Milan, Italy – at the same time as launching a new type of Vapour Product, Vype Pebble.
In 2015, we launched our first Tobacco Heating Product, iFuse, in Romania. This electronic device heats a nicotine-containing liquid into an inhalable vapour, which then passes through a tobacco section, delivering tobacco flavour to the consumer.
In November 2016, we announced the launch of glo in Japan. Similar to a cigarette, but with reduced risk potential, glo heats rather than burns tobacco, producing around 90% less toxicants* than a conventional cigarette.
In 2014, we became the first tobacco company to have a nicotine inhalation product – Voke – licensed as a medicine. However, at the beginning of 2017 we announced that our main focus and priority in the rapidly evolving NGP category would be on Vapour and Tobacco Heating Products. As a result, we assigned all rights to the Voke brand and transferred all product and manufacturing-related intellectual property to Kind Consumer, the company we originally licenced the Voke technology from. Under this new agreement, Kind Consumer will be fully responsible for Voke’s future development.